Published in Arch Dermatol on November 01, 2006
Pyoderma gangrenosum of the breast treated with intravenous immunoglobulin. J Dermatol Case Rep (2013) 0.89
Pyoderma Gangrenosum: A Rare Cause of Cutaneous Ulceration and One Easily Misdiagnosed. Case Rep Pediatr (2016) 0.75
A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet (2010) 8.48
Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol (2012) 4.52
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med (2014) 3.36
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol (2003) 3.28
Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum (2005) 2.93
Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. Hum Mol Genet (2008) 2.42
Noninvasive measurement of skin autofluorescence is increased in patients with systemic sclerosis: an indicator of increased advanced glycation endproducts? J Rheumatol (2012) 2.03
Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol (2004) 1.84
Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol (2003) 1.68
Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohort. J Invest Dermatol (2007) 1.44
Beyond skin: the need for a new approach to the management of psoriasis in primary care. Br J Gen Pract (2012) 1.42
Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin (2005) 1.36
Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov (2013) 1.35
Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes. J Invest Dermatol (2013) 1.32
Glucocorticoid sensitivity is determined by a specific glucocorticoid receptor haplotype. J Clin Endocrinol Metab (2004) 1.29
Current and future management of psoriasis. Lancet (2007) 1.29
The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest (2008) 1.27
Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol (2003) 1.26
Epidermal Langerhans cell migration and sensitisation to chemical allergens. APMIS (2003) 1.25
Why some women look young for their age. PLoS One (2009) 1.24
Noninvasive imaging techniques in the assessment of scleroderma spectrum disorders. Arthritis Rheum (2009) 1.23
Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors. J Am Acad Dermatol (2005) 1.17
Impaired Langerhans cell migration in psoriasis. J Exp Med (2006) 1.16
Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum (2005) 1.16
Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol (2007) 1.10
The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. J Psychosom Res (2004) 1.06
Diminished neural and cognitive responses to facial expressions of disgust in patients with psoriasis: a functional magnetic resonance imaging study. J Invest Dermatol (2009) 1.02
Psychological stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perceptions, coping and alexithymia. Br J Clin Psychol (2002) 1.00
The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Arch Dermatol Res (2008) 0.99
Tissue section AFM: In situ ultrastructural imaging of native biomolecules. Matrix Biol (2010) 0.97
Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Ann Rheum Dis (2011) 0.96
Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol (2004) 0.96
Evaluation of educational methods in dermatology and confidence levels: a national survey of UK medical students. Int J Dermatol (2011) 0.96
Alexithymia in patients with psoriasis: clinical correlates and psychometric properties of the Toronto Alexithymia Scale-20. J Psychosom Res (2005) 0.96
Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol (2007) 0.95
Infliximab for the treatment of psoriasis. Expert Opin Biol Ther (2006) 0.93
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol (2011) 0.92
The effects of acute social stress on epidermal Langerhans' cell frequency and expression of cutaneous neuropeptides. J Invest Dermatol (2007) 0.92
Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol (2006) 0.91
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) (2013) 0.90
'On the surface': a qualitative study of GPs' and patients' perspectives on psoriasis. BMC Fam Pract (2013) 0.90
Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol (2008) 0.90
The use of retinoids in the treatment of photoaging. Dermatol Ther (2006) 0.89
A European perspective on the challenges of managing psoriasis. J Am Acad Dermatol (2006) 0.89
The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol (2002) 0.89
Low-dose ultraviolet radiation selectively degrades chromophore-rich extracellular matrix components. J Pathol (2010) 0.88
Targeting cognitive-behaviour therapy to patients' implicit model of psoriasis: results from a patient preference controlled trial. Br J Clin Psychol (2004) 0.88
Langerhans cell mobilization distinguishes between early-onset and late-onset psoriasis. J Invest Dermatol (2010) 0.87
The future of biological therapies. Semin Cutan Med Surg (2010) 0.87
Measurement of cytokine expression and Langerhans cell migration in human skin following suction blister formation. Exp Dermatol (2004) 0.87
Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Curr Med Res Opin (2008) 0.86
The CX3CL1-CX3CR1 system and psoriasis. Exp Dermatol (2006) 0.86
Facial appearance reflects human familial longevity and cardiovascular disease risk in healthy individuals. J Gerontol A Biol Sci Med Sci (2012) 0.86
Filaggrin null alleles are not associated with psoriasis. J Invest Dermatol (2007) 0.86
Retinoic acid receptor alpha expression and cutaneous ageing. Mech Ageing Dev (2004) 0.85
A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study. Pharmacogenomics (2011) 0.84
Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin Dermatol (2008) 0.84
Humoral autoimmune responses to the squamous cell carcinoma antigen protein family in psoriasis. J Invest Dermatol (2008) 0.84
Expression of microRNA-184 in keratinocytes represses argonaute 2. J Cell Physiol (2013) 0.83
Exploring the role of prolactin in psoriasis. Arch Dermatol Res (2012) 0.83
Divergent beliefs about psoriasis are associated with increased psychological distress. J Invest Dermatol (2004) 0.82
Cross-linking of structural proteins in ageing skin: an in situ assay for the detection of amine oxidase activity. Biogerontology (2012) 0.82
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol (2012) 0.82
Associations between UVR exposure and basal cell carcinoma site and histology. Cancer Lett (2004) 0.81
Genomic-driven insights into changes in aging skin. J Drugs Dermatol (2009) 0.81
Photoageing: the darker side of the sun. Photochem Photobiol Sci (2005) 0.81
The Simplified Psoriasis Index (SPI): a practical tool for assessing psoriasis. J Invest Dermatol (2013) 0.80
Can stress reduction interventions improve psoriasis? A review. Psychol Health Med (2012) 0.80
No association between polymorphisms in the interleukin-15 gene and early-onset psoriasis in a UK cohort suggests heterogeneity for this susceptibility locus identified in Chinese psoriasis patients. J Invest Dermatol (2008) 0.80
Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. Dermatology (2010) 0.79
Efficacy of anti-aging products for periorbital wrinkles as measured by 3-D imaging. J Cosmet Dermatol (2009) 0.79
Pathogenic aspects of cutaneous photoaging. J Cosmet Dermatol (2005) 0.79
Illness perception in individuals with atopic dermatitis. Psychol Health Med (2007) 0.79
Mind the (gender) gap: does prolactin exert gender and/or site-specific effects on the human hair follicle? J Invest Dermatol (2009) 0.78
Optimal management of severe plaque form of psoriasis. Am J Clin Dermatol (2005) 0.78
Damage to skin extracellular matrix induced by UV exposure. Antioxid Redox Signal (2014) 0.78
Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. J Dermatolog Treat (2015) 0.78
Increased blood levels of IgG reactive with secreted Streptococcus pyogenes proteins in chronic plaque psoriasis. J Invest Dermatol (2007) 0.78
Assessment of adapalene gel for the treatment of actinic keratoses and lentigines: a randomized trial. J Am Acad Dermatol (2003) 0.77
Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol (2007) 0.77
Exploring the mode of action of dithranol therapy for psoriasis: a metabolomic analysis using HaCaT cells. Mol Biosyst (2015) 0.77
Dr. Murray, et al reply. J Rheumatol (2013) 0.77
A tooth for an eye: cicatricial pemphigoid and the osteo-odonto-keratoprosthesis. Arch Dermatol (2010) 0.77
Utilizing the hair follicle to dissect the regulation and autocrine/paracrine activities of prolactin in humans. Am J Physiol Endocrinol Metab (2012) 0.76
Tumour necrosis factor alpha, interferon gamma and substance P are novel modulators of extrapituitary prolactin expression in human skin. PLoS One (2013) 0.76
Evidence for the presence of bacteria in the blood of psoriasis patients. Arch Dermatol Res (2010) 0.76
Biological therapy for psoriasis. Br J Hosp Med (Lond) (2006) 0.76
In search of the source of hyperprolactinaemia in systemic lupus erythematosus. Clin Exp Rheumatol (2011) 0.76
A review of tazarotene in the treatment of photodamaged skin. Clin Interv Aging (2008) 0.76
Differential expression of elastic fibre components in intrinsically aged skin. Biogerontology (2011) 0.76
Resetting the research agenda for psoriasis. J Invest Dermatol (2003) 0.75
Patchy hair loss in an otherwise healthy man. CMAJ (2013) 0.75
Gougerot-Carteaud still an enigma after all these years. J Dermatolog Treat (2002) 0.75
Disentangling the effects of circulating IGF-1, glucose, and cortisol on features of perceived age. Age (Dordr) (2015) 0.75
Liver X receptor β: maintenance of epidermal expression in intrinsic and extrinsic skin aging. Age (Dordr) (2009) 0.75
Proceedings of the Facial and Aesthetics Conference and Exhibition, Royal College of Physicians, London, 26-27 June. J Cosmet Laser Ther (2004) 0.75
Therapeutic potential of macrolide immunosuppressants in dermatology. Expert Opin Investig Drugs (2004) 0.75
Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis. J Dermatolog Treat (2012) 0.75